Cargando…

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice

The COVID-19 pandemic caused significant human health and economic consequences. Due to the ability of SARS-CoV-2 to spread rapidly and to cause severe disease and mortality in certain population groups, vaccines are essential for controlling the pandemic in the future. Several licensed vaccines hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalodimou, Georgia, Jany, Sylvia, Freudenstein, Astrid, Schwarz, Jan Hendrik, Limpinsel, Leonard, Rohde, Cornelius, Kupke, Alexandra, Becker, Stephan, Volz, Asisa, Tscherne, Alina, Sutter, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222707/ https://www.ncbi.nlm.nih.gov/pubmed/37243266 http://dx.doi.org/10.3390/v15051180

Ejemplares similares

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
por: Tscherne, Alina, et al.
Publicado: (2021)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
por: Langenmayer, Martin C., et al.
Publicado: (2023)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2019)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
por: Do, Kim Thi Hoang, et al.
Publicado: (2023)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
por: Veit, Svenja, et al.
Publicado: (2018)

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
por: Fathi, Anahita, et al.
Publicado: (2023)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
por: Fathi, Anahita, et al.
Publicado: (2022)

Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S
por: Langenmayer, Martin C., et al.
Publicado: (2018)

MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination
por: Meyer zu Natrup, Christian, et al.
Publicado: (2023)

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
por: Meyer zu Natrup, Christian, et al.
Publicado: (2022)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
por: Chege, GK, et al.
Publicado: (2012)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
por: Volz, Asisa, et al.
Publicado: (2018)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations
por: Palgen, Jean-Louis, et al.
Publicado: (2020)

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice
por: Stephan, Ann-Sophie, et al.
Publicado: (2023)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
por: Förster, Reinhold, et al.
Publicado: (2020)

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
por: Ba, Lei, et al.
Publicado: (2007)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice
por: Chapman, Ros, et al.
Publicado: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
por: Green, Christopher A., et al.
Publicado: (2019)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination
por: Lorenzo, Gema, et al.
Publicado: (2018)

The 90 MVA transformer
Publicado: (1974)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
por: Rollier, Christine S., et al.
Publicado: (2016)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4mso9rfnke46722na8qfnai3o9